logo-loader
viewe-Therapeutics PLC

e-Therapeutics begins experimental testing on first set of compounds for coronavirus treatment

e-Therapeutics PLC's (LON:ETX) chief scientific officer Alan Whitmore speaks to Proactive London's Andrew Scott after announcing they've begun experimental testing on the first set of compounds for the treatment of coronavirus (COVID-19) identified using its proprietary network-driven drug discovery (NDD) platform.

He says the initial compound set, which has the potential to address both viral replication and the associated excessive immune response, will be tested by WuXi AppTec utilising its relevant cell-based assays.

Quick facts: e-Therapeutics PLC

Price: 17.45 GBX

AIM:ETX
Market: AIM
Market Cap: £56.26 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics PLC named herein, including the promotion by the Company of e-Therapeutics PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 surges as more countries across Europe ease...

Headlines from the Proactive UK newsroom. The FTSE 100 surged 143 points higher this morning to 5,943 as more countries across Europe started to ease their lockdown restrictions. Ryanair Holdings plc (LON:RYA) has slammed its rivals for receiving state aid as its predicted a loss of over...

2 weeks, 2 days ago

2 min read